Expression of CD15 antigen in urinary bladder transitional cell carcinoma

Area of Science:

• Oncology
• Pathology
• Immunohistochemistry

Background:

• Transitional cell carcinoma (urothelial carcinoma) is the most common type of bladder cancer.
• Prognostic markers are crucial for guiding treatment decisions in bladder cancer.
• CD15 antigen expression has been investigated as a potential biomarker in various cancers.

Purpose of the Study:

• To investigate the correlation between CD15 antigen expression, detected by monoclonal antibody MC2, and the prognosis of transitional cell carcinoma of the bladder.
• To explore the potential role of CD15 in cell adhesion within bladder tumors.

Main Methods:

• Retrospective review of 91 biopsy specimens from patients with transitional cell carcinoma of the bladder (ages 38-94).
• Immunohistochemical staining using monoclonal antibody MC2 to detect CD15 antigen expression.
• Analysis of staining patterns in relation to tumor differentiation, type, grade, stage, and patient survival.

Main Results:

• CD15 antigen expression varied across different tumor types and differentiation levels.
• Stronger expression was observed in superficial cells of well-differentiated papillary lesions, while weaker expression was seen in solid or invasive tumors.
• A correlation was found between MC2 expression and tumor type in the invasive component, suggesting a role in cell adhesion.
• No significant correlation was identified between CD15 antigen staining and patient survival.

Conclusions:

• CD15 antigen expression is not a reliable prognostic indicator for transitional cell carcinoma of the bladder.
• Tumor type, grade, and stage remain the most significant prognostic factors for urothelial tumors.
• The cell surface carbohydrate detected by MC2 may play a role in cell adhesion in bladder cancer.